Boston Therapeutics today announces it has initiated a research study with the University of Minnesota on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. Entitled “NMR studies of PAZ320 with sugar hydrolyzing enzymes”, the study will be conducted by Kevin H. Mayo, Ph.D., a professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota, Minneapolis.
Dr. Mayo commented, “PAZ320 appears to be a promising compound in the treatment of diabetes and deserves closer evaluation by the scientific community. This Boston Therapeutics-supported investigation is designed to assess biomolecular interactions between PAZ320 and various sugar hydrolyzing enzymes, and should contribute to understanding PAZ320′s mechanism of action on the molecular level.”
David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, “We are greatly encouraged by the results obtained to date regarding the ability of PAZ320 to reduce the elevation of post-meal blood glucose. We expect this new study at the University of Minnesota will deepen our understanding of this compound on a molecular level, and strengthen our knowledge of its potential as a drug for diabetes patients.”
The study’s purpose is to provide molecular-level information on PAZ320 and its mechanism of action. More particularly, the study is intended to better characterize PAZ320 galactomannan, and assess interactions of PAZ320 with various sugar-hydrolyzing enzymes (e.g., glucosidase and maltase). Furthermore, it may produce insights into the allosteric properties of PAZ320 with enzymes, gauge the effect of PAZ320 on enzyme-mediated sugar hydrolysis, and compare PAZ320 with other diabetes drugs.
Boston Therapeutics is a developer of drugs based on complex carbohydrate chemistry to treat diabetes. It is primarily focused currently on developing and commercializing therapeutic molecules for Type 2 diabetes, of which PAZ320 is one.
For additional information, visit www.BostonTI.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
